The exercise component mattered after treatment ended
A follow-up of a randomized trial found better weight maintenance after an exercise-plus-liraglutide program than after liraglutide alone. The finding supports including sustainable activity in the longer-term plan. It does not prove that exercise can replace semaglutide or tirzepatide for every person.[1]
The question here is what may remain useful after a structured treatment phase ends. It differs from asking which medicine produces the greatest initial weight loss. That longer view is particularly relevant when coverage, affordability or a planned transition could interrupt treatment.
Understand the two stages
The original study began with a supervised low-calorie phase, then randomized participants to exercise, liraglutide, both or placebo for a year. The later report assessed a further year without assigned treatment. Of 166 participants completing the treatment phase, 109 attended the follow-up. Combined treatment was associated with about 5.1 kg lower weight than liraglutide alone at the later assessment.[2] [1]
| Reading the evidence | What it tells us |
|---|---|
| Initial phase | A structured, supervised weight-loss intervention preceded randomization. |
| Treatment phase | Exercise, liraglutide, both or placebo. |
| Later follow-up | No assigned treatment for another year. |
| Important limitation | Not all treatment completers attended the later assessment. |
Attrition means the later result should be read with care. The people who return for follow-up may differ from those who do not. The finding remains useful, but it is not a universal forecast of what happens when treatment stops.
Do not copy the trial as a home regimen
The initial low-calorie phase and supervised activity program were research interventions. This article does not recommend recreating them without clinical support. The transferable idea is to develop an activity pattern that can continue beyond a particular prescription or program, with suitable guidance for the individual.
That may mean identifying an enjoyable activity, arranging a realistic place and time or obtaining help for pain or mobility limitations. These are practical planning choices. The trial does not establish that one exercise format is mandatory for every reader.
Weight and strength are not interchangeable
A lower scale weight does not directly measure strength, fitness or the ability to complete daily tasks. Our body-composition article explains why lean mass and muscle are not identical measurements. The nutrition guide adds the food-planning side of the conversation.
Keep a small number of meaningful functional goals beside weight. An example might be returning to a familiar walk or finding an activity that fits the week consistently. These goals can help a clinician or qualified exercise professional understand what support is needed without turning every day into a performance test.
Plan for continuity before a disruption
Our semaglutide withdrawal article and tirzepatide maintenance article describe different medicines and study designs. Do not combine their numbers into a single prediction. Together, they make a strong case for discussing the period after active treatment rather than leaving it unplanned.
The Form Health review examines ongoing clinical and dietitian care; the Enhance.MD review discusses a program advertising nutrition and fitness support. Our guides help clarify what support actually means in each service.
Use the question builder to ask which parts of the plan can continue if access changes. The trial supports a lasting role for an exercise component, while leaving medicine changes and individualized activity advice with the clinical team.
Maintenance is a phase with its own support needs
A program can be excellent at organizing the first weeks yet leave the later phase undefined. The trial’s follow-up makes that gap visible. What happens when scheduled sessions end, a prescription changes or the original source of accountability disappears? A lasting routine needs a place in ordinary life rather than only in the treatment program.
That does not mean every person should manage maintenance alone. It means identifying which supports can continue: a suitable activity setting, a clinician who reviews progress, practical nutrition help or a realistic schedule. A service comparison should ask what remains available after an initial package. The answer may matter more to a longer-term decision than another introductory feature that is used only once.
The maintenance conversation can begin while treatment is going well. It does not require an intention to stop medicine; it simply makes the continuing supports visible before an unexpected change forces a rushed decision.